Jennifer Sturgill, DO, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact on heart failure care of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 under the Inflation Reduction Act (IRA).
Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 on heart failure care.
She presented on value-based care at our recent Institute for Value-Based Medicine® event held with the Zangmeister Cancer Center of Columbus, Ohio.
Transcript
Can you provide insight into how the current drug shortage has affected primary care for patients?
You know, the drug shortages have mostly been on antibiotics and ADHD [attention-deficit/hyperactivity disorder] medications. The antibiotics are a little bit easier to deal with because we can provide alternatives. And I think it really has kind of forced providers to maybe get out of their comfort zone instead of just always prescribing that one antibiotic they're comfortable with; they can pull up the guidelines and see what's the first, second line and change it to something different.
The ADHD medications have been a little bit more difficult, and that really has been the pressure put on the patient. They're the ones having to go to different pharmacies to find out if the medication is available. We really don't have a great solution or workaround to this. I think it's getting a little bit better, but it's still a huge burden on the patients.
How might CMS’ announcement of the 10 drugs subject to price negotiation under the Inflation Reduction Act affect primary care when negotiated prices take effect?
I'd say not just primary care, but for patients in general, looking at the list, in particular, the SGLT-2 [sodium-glucose cotransporter-2] inhibitors, they are hugely important now in the treatment of CHF. And, you know, we have an aging population, and people are developing congestive heart failure, they're living longer, and they're living longer chronically ill. And now when we're starting patients on medications, we can give them a coupon and hope that they're able to get that first month supply. But it really takes a lot of effort on the patient's behalf and on the primary care provider to make sure that their patient is able to stay on the medication, that there's no interruption in care.
We know that CHF is one of the leading readmission diagnoses for patients. These patients decompensate quickly and often, and it's not helping their medical condition if they're not able to stay on a medication. So, it's very exciting to see that these medications are going to be addressed.
And then the other medications, the anticoagulants with Eliquis [apixaban] and Xarelto [rivaroxaban], we know that these are safer, [have] fewer interactions, require less monitoring than Coumadin [warfarin]. These are the medications we are prescribing for patients, and a lot of patients are on them. And again, it's going to be very helpful to know that we don't necessarily have to jump through a lot of hoops to make sure the patient can initially fill the medication, but then also stay on it.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More